Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)

NCT01088724 is registered in ClinicalTrials.gov with A.O. Ospedale Papa Giovanni XXIII as lead sponsor.

NCT NCT01088724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01088724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD)
Lead sponsor
A.O. Ospedale Papa Giovanni XXIII
Phase
Phase 4
Overall status
Completed
Start date
February 28, 2002
Completion date
March 31, 2010
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non burkitt, post-transplant lymphoproliferative disease (ptld)